Insider Selling: Maze Therapeutics (NASDAQ:MAZE) SVP Sells 2,500 Shares of Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) SVP Amy Bachrodt sold 2,500 shares of Maze Therapeutics stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $29.44, for a total transaction of $73,600.00. Following the completion of the transaction, the senior vice president owned 12,965 shares in the company, valued at approximately $381,689.60. The trade was a 16.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Amy Bachrodt also recently made the following trade(s):

• On Monday, February 2nd, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $46.04, for a total transaction of $230,200.00.
• On Thursday, January 22nd, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $45.52, for a total transaction of $227,600.00.
• On Friday, January 2nd, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $39.15, for a total value of $195,750.00.

Maze Therapeutics Stock Down 1.2%

Shares of MAZE traded down $0.34 during trading hours on Thursday, hitting $28.71. The company had a trading volume of 780,343 shares, compared to its average volume of 709,583. Maze Therapeutics, Inc. has a 52-week low of $6.71 and a 52-week high of $53.65. The stock’s 50 day moving average price is $44.79 and its 200 day moving average price is $37.94. The firm has a market cap of $1.43 billion, a P/E ratio of -8.89 and a beta of 5.14.

Maze Therapeutics (NASDAQ:MAZE) last issued its earnings results on Wednesday, March 25th. The company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.08.

Institutional Investors Weigh In On Maze Therapeutics

A number of large investors have recently modified their holdings of the stock. Royal Bank of Canada boosted its stake in shares of Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after purchasing an additional 363 shares in the last quarter. Ameritas Investment Partners Inc. raised its stake in Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after buying an additional 738 shares in the last quarter. California State Teachers Retirement System lifted its holdings in Maze Therapeutics by 138.0% in the fourth quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock worth $55,000 after buying an additional 766 shares during the period. Police & Firemen s Retirement System of New Jersey boosted its position in Maze Therapeutics by 18.5% during the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 5,961 shares of the company’s stock valued at $247,000 after acquiring an additional 931 shares in the last quarter. Finally, GF Fund Management CO. LTD. bought a new stake in Maze Therapeutics during the 4th quarter valued at approximately $39,000.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on MAZE. Truist Financial started coverage on Maze Therapeutics in a research note on Tuesday, March 17th. They set a “buy” rating and a $68.00 price objective for the company. Weiss Ratings reiterated a “sell (d)” rating on shares of Maze Therapeutics in a report on Thursday, January 22nd. Lifesci Capital raised shares of Maze Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Mizuho raised shares of Maze Therapeutics to a “strong-buy” rating in a report on Wednesday, March 11th. Finally, Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Three research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $66.44.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.